About Senores Pharmaceuticals Ltd
Senores Pharmaceuticals is engaged in the business of manufacturing, marketing and trading of pharmaceuticals and allied products and also providing management and consultancy services.
Founded
2017
CEO
Sanjay Majmudar
Employees
194
HQ
Ahmedabad, India
Finished Products
1Sale of products
₹71.50Cr2Consultancy Income
₹8.64Cr3Product Development Income
₹4.72Cr4Export Incentives
₹0.05Cr5Other Operating Revenue
₹0.02CrRaw Materials
1Purchase
₹34.75Cr2Raw Material Consumed
₹6.00CrAbout Senores Pharmaceuticals Ltd
Senores Pharmaceuticals is engaged in the business of manufacturing, marketing and trading of pharmaceuticals and allied products and also providing management and consultancy services.
Founded:2017
CEO:Sanjay Majmudar
Employees:194
HQ:Ahmedabad, India
Finished Products
1Sale of products
₹71.50Cr2Consultancy Income
₹8.64Cr3Product Development Income
₹4.72Cr4Export Incentives
₹0.05Cr5Other Operating Revenue
₹0.02CrRaw Materials
1Purchase
₹34.75Cr2Raw Material Consumed
₹6.00CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹1,599
52W Low
₹662
Volume170.20K
Avg VolumeN/A
Beta0.91
Dividend Yield0.00%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
51.16x
Valuation
P/B Ratio
7.17x
Valuation
EPS
₹28.41
Valuation
Dividend Yield
0.00%
Valuation
ROE
12.36%
Profitability
ROCE
14.43%
Profitability
Revenue by Segment
Contribution & growth by business line
Regulated Markets Business
+68.7%61.5%
₹244.84 Cr
Critical Care Injectables Business
+2021.7%30.4%
₹121.15 Cr
API Business
+1.2%3.5%
₹14.06 Cr
Other Operational income
+84.7%2.6%
₹10.27 Cr
Emerging Markets Business
-82.1%2.0%
₹7.93 Cr
Geographical Revenue Split
Domestic vs international exposure
Domestic
26.3%
International
73.7%
Outside India73.7%
Within India26.3%
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.37x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
124.2%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.